A practical reference on regulatory status: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-07-25. Anything still debated is marked as such rather than presented as settled.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
== Surgery == While weight loss is beneficial in improving glycemic control in patients with T2D, maintaining significant weight loss can be challenging. People with diabetes who have a body mass index (BMI) of 35 or higher, and who have been unable to lose weight otherwise, bariatric surgery offers a viable option to help achieve that goal. In 2018, a Patient-Centered Outcomes Research Institute funded study was published which analyzed the effects of three common types of bariatric surgery on sustained weight loss and long-lasting glycemic control in patients with T2D. The results of this study demonstrated that five years after bariatric surgery, there was significant weight loss in a large majority of patients. In addition, and more importantly, this study showed that, in patients with type 2 diabetes with a BMI of 35 or higher, bariatric surgery has the potential to lead to complete remission of diabetes in as many as 40% of those people who have the procedure. Like any operation, bariatric surgery is not without risks and complications, and those risks need to weighed against the potential benefits in anyone considering the procedure.
== The role in human pregnancy == In humans, a certain subtype of cells of the placenta, namely the extravillous trophoblasts, express the enzyme and secrete it into the blood stream of a pregnant woman. During pregnancy, DAO helps maintaining fetal growth and development by regulating histamine levels. DAO levels in the blood circulation increase vastly in pregnant women suggesting a protective mechanism against adverse histamine. Histamine is a potent vasodilator and can cause uterine contractions, which can lead to premature labor. DAO in the placenta breaks down histamine to prevent its accumulation and maintain a healthy pregnancy. Low levels of DAO in the placenta may contribute to preeclampsia, a pregnancy-related disorder characterized by mother's high blood pressure and damage to mother's organs such as the liver and kidneys; the baby may also be affected if the condition is severe or left untreated, but it is not the primary target of the disorder. Lowered diamine oxidase values in maternal blood in early pregnancy might be an indication for trophoblast-related pregnancy disorders like early-onset preeclampsia.
Marxism–Leninism is a communist ideology that became the largest faction of the communist movement following the October Revolution. It was the predominant ideology of most communist governments in the 20th century. It was developed in the Soviet Union by Joseph Stalin and drew on Bolshevism, Leninism, and Classical Marxism. It was the state ideology of the Soviet Union, Soviet satellite states in the Eastern Bloc, and various countries in the Non-Aligned Movement and Third World during the Cold War, as well as the Communist International. It is the ideology of the ruling parties of China, Cuba, Laos, and Vietnam, as well as other communist parties. The state ideology of North Korea is derived from Marxism–Leninism. Marxism–Leninism holds that a two-stage communist revolution is needed to replace capitalism. A vanguard party, organized through democratic centralism, seizes power on behalf of the proletariat and establishes a one-party communist state. The state controls the means of production, suppresses opposition, counter-revolution, and the bourgeoisie, and promotes Soviet collectivism, to pave the way for a communist society that is classless and stateless. After Lenin's death in 1924, Marxism–Leninism became a distinct movement in the Soviet Union when Stalin and his supporters gained control of the Communist Party of the Soviet Union (CPSU). It rejected the notion among Western Marxists of world revolution as a prerequisite for building socialism, in favour of the concept of socialism in one country.
== Early life and career == Reid, who originally played football for the North Balwyn Methodists, played two senior games for Hawthorn in the 1966 VFL season and one further game the following year. Reid was a member of Preston's 1968 and 1969 Victorian Football Association premiership teams. Having graduated from university with a medical degree while at Preston, Reid worked as a club doctor with Richmond from 1976 to 1979.
Sources: en.wikipedia.org
The basic process of protein production is the addition of one amino acid at a time to the end of a forming polypeptide chain. This operation is performed by a ribosome. A ribosome is made up of two subunits, in the eukaryote a small (40S) subunit, and a large (60S) subunit. These subunits come together before the translation of mRNA into a protein to provide a location for translation to be carried out and a polypeptide to be produced. The choice of amino acid type to add is determined by a messenger RNA (mRNA) molecule. Each amino acid added is matched to a three-nucleotide subsequence of the mRNA. For each such triplet possible, the corresponding amino acid is accepted. The successive amino acids added to the chain are matched to successive nucleotide triplets in the mRNA. In this way, the sequence of nucleotides in the template mRNA chain determines the sequence of amino acids in the generated amino acid chain. The addition of an amino acid occurs at the C-terminus of the peptide; thus, translation is said to be amine-to-carboxyl directed. The mRNA carries genetic information encoded as a ribonucleotide sequence from the chromosomes to the ribosomes. The ribonucleotides are "read" by translational machinery in a sequence of nucleotide triplets called codons. Each of those triplets codes for a specific amino acid. The ribosome molecules translate this code to a specific sequence of amino acids. The ribosome is a multi subunit structure containing ribosomal RNA (TRNA) and proteins. It is the "factory" where amino acids are assembled into proteins.
== Materials used == Injectable fillers are composed of a wide range of natural and synthetic biomaterials, which can be categorized as resorbable or non-resorbable polymers. Injectable fillers are frequently formulated as hydrogels composed of hydrophilic polymer networks that can retain large amounts of water while maintaining structural integrity. Common materials include naturally derived polymers such as hyaluronic acid, gelatin, collagen, chitosan, alginate, and polysaccharides, as well as synthetic polymers like polyethylene glycol (PEG), poly(lactic acid), poly(methyl methacrylate), polyacrylamide, and dextran. These materials are often selected for their biocompatibility and structural similarity to the extracellular matrix, enabling integration with surrounding tissues. To enable in situ gelation, polymers are typically functionalized with reactive groups such as phenols, amines, or glutamine residues, allowing controlled crosslinking after injection. In advanced formulations, these hydrogel matrices may also serve as carriers for therapeutic fillers, including cells, proteins, or drugs, expanding their functionality beyond structural augmentation. Hyaluronic acid
To allow bone mineralization to take place, osteoblasts secrete tissue-nonspecific alkaline phosphatase into the osteoid to break down pyrophosphate, an extracellular inhibitor of hydroxyapatite precipitation which otherwise prevents precipitation of hydroxyapetite crystals from extracellular fluid which is supersaturated in Ca2+ and PO3−4 ions.
Sources: en.wikipedia.org
Chen, Li & Shi (2026) study the cranial morphology and phylogenetic affinities of Tossunnoria pseudibex, recover the species as a member of the bovid tribe Urmiatheriini, and interpret its caprin-like morphology as a result of convergent evolution. Revision of the type material of Pachygazella grangeri is published by Bai, Wang & Dong (2026). Evidence from the study of tooth wear of extant and Pleistocene springboks, indicative of variability of dietary signals in members of the same species both within and across different biomes, is presented by Walls et al. (2026). Dumitru et al. (2026) determine that deposition of fossils of Myotragus antiquus in Cova des Fum (Mallorca, Spain) happened between 3.60 and 3.45 million years ago, indicating that M. antiquus lived years earlier than indicated by previous estimates. Armaroli et al. (2026) provide new information on the late Pleistocene Alpine ibex population from Riparo Dalmeri (Italy) on the basis of the study of strontium, carbon and oxygen isotopic composition of their remains, ancient DNA data and radiocarbon dating, reporting evidence of stable density of the studied population despite intensive hunting and consistent human presence, as well as evidence dietary differences between sexes in the studied population. Sorbelli et al. (2026) describe fossil material of "Alephis" tigneresi from the Pliocene strata from Camp dels Ninots (Spain), and assign this species to the genus Parabos. Liang et al.
== Dystrophies, myositis, and motor neuron conditions == Pathologic atrophy of muscles can occur with diseases of the motor nerves or diseases of the muscle tissue itself. Examples of atrophying nerve diseases include Charcot-Marie-Tooth disease, poliomyelitis, amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease), and Guillain–Barré syndrome. Examples of atrophying muscle diseases include muscular dystrophy, myotonia congenita, and myotonic dystrophy. Changes in Na+ channel isoform expression and spontaneous activity in muscle called fibrillation can also result in muscle atrophy. A flail limb is a medical term which refers to an extremity in which the primary nerve has been severed, resulting in complete lack of mobility and sensation. The muscles soon wither away from atrophy.
== Control and detection == The use of bracken fern as human food is mainly a historical question. The rhizomes of these plants served as human food in Scotland during the First World War. In America (USA, Canada), Russia, China and Japan, fern is grown commercially for human use. The usual procedure that is performed before eating the plant is to pre-treat the fern with boiling water in the presence of different chemicals, such as sodium bicarbonate and wood ash, to degrade or inactivate ptaquiloside and other toxic agents. Nevertheless, some carcinogenic activity persists even after the treatment. As shown by Kamon and Hirayama, the risk of oesophageal cancer was increased approximately by 2.1 in men and 3.7 in women who regularly consume bracken in Japan. Recent researches have suggested that sulfur-containing amino acids can potentially be used under appropriate conditions as detoxifying agents for ptaquiloside and selenium supplementation can prevent as well as reverse the immunotoxic effects induced by ptaquiloside. Ptaquiloside in the aqueous extract of bracken can be detected using different instrumental methods: thin-layer chromatography–densitometry (TLC-densitometry), high-performance liquid chromatography (HPLC), gas chromatography–mass spectrometry (GCMS), and liquid chromatography–mass spectrometry (LC-MS).
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.